arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 10/2024 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    NEW ON THE MARKET

    Osteoporosis drug abaloparatide (ELADYNOS)

    Background: osteoanabolic osteoporosis drugs

    Risankizumab (SKYRIZI) for ulcerative colitis

    IN BRIEF

    Despite the SELECT trial: semaglutide as WEGOVY remains exclusively a lifestyle drug

    ESC guideline recommends screening for atrial fibrillation despite new negative trials
    free

    Blood pressure measurement: the correct arm position

    Supply shortages, stockpiling, exemptions for imports: no improvement in the supply of medicines in sight

    a-t READERS QUESTIONS AND COMMENTS

    Oviva direkt for obesity: overreaching marketing by the provider of the digital health application

    Ivermectin-containing cream SOOLANTRA against rosacea: drastic price increase

    BEWARE MISINFORMATION

    Is a reduction in all-cause mortality for the COPD inhaler TRIXEO AEROSPHERE actually proven?

    SIDE EFFECTS

    Fibroadenomas with ciclosporin

    Finasteride, dutasteride: EMA examines data on suicidality

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles

    Wir schätzen Ihr Feedback

    Nehmen Sie an unserer Umfrage teil!